HCW Biologics (HCW Biologics (HCWB)) had a day to remember on Friday. The biotech stock shot up 230% after the company reported quarterly results that were, well, dramatically better than a year ago. We're talking earnings per share of $0.37 and quarterly sales of $6.54 million — compared to just $5,065 in the same period last year. That's not a typo.

What's driving the excitement? A few things. First, the company's licensing deal with Wugen has now generated over $16 million in aggregate revenue since 2020. That's a nice recurring stream. And just this quarter, HCW closed an exclusive worldwide licensing agreement with Trimmune for the in vivo rights to HCW11-006. The upfront fee: $3.5 million in cash plus another $3.5 million in the form of a transferable minority equity stake in Trimmune. Not bad for a company that was sitting on just $1.23 million in cash at the end of the quarter.

But the real story might be the pipeline. HCW is developing HCW9302 for autoimmune disorders, and CEO Hing C. Wong is optimistic. "HCW9302 was selected as the lead product candidate for the Company's autoimmune program because it has demonstrated relatively high IL-2Rα affinity and sustains serum exposure, which implies it has a strong profile for the treatment of autoimmune disorders," Wong said in the press release. The company is on track to release preliminary clinical data from the first two dose levels of a Phase 1 study in alopecia areata in the first half of 2026. Two clinical sites are actively enrolling patients, and enrollment is on schedule.

Now, the sobering part. HCW ended the quarter with only $1.23 million in cash, down from $1.95 million a year ago. The company acknowledges there's "substantial doubt" about its ability to continue as a going concern without additional funding. It says it's making early progress on a multistep financing plan, but that's a big if. And Nasdaq granted the company a hearing on May 5 to appeal a potential delisting tied to non-compliance with the $1 minimum bid price rule. At around $1.11 per share, HCW is just barely above that threshold.

So, is this a turnaround story or a dead cat bounce? The licensing revenue and pipeline progress are real, but the cash position is precarious. Investors are betting the company can secure funding and deliver on its clinical milestones. For now, the market is cheering — but the real test will come when the data hits.